The European Investment Bank grants 75 million euros to the Institut Pasteur in Dakar for a new vaccine…

Large-scale financing of the new vaccine manufacturing plant at the Institut Pasteur in Dakar, a leader in the field in Africa. The facility is expected to significantly reduce Africa’s reliance on imported vaccines and support equal access to vaccines, producing up to 300 million doses per year against COVID-19 and others endemic diseases. This financing reflects the EIB’s commitment (www.EIB.org) strong involvement in Africa, in particular through its new BEI Global initiative bringing together its activities outside the European Union, in close cooperation with the other EU institutions within the framework of Team Europe.

On Thursday June 2, 2022, the Institut Pasteur de Dakar and the European Investment Bank (EIB) announced the conclusion of a financing agreement of 75 million euros to support the construction of the new MADIBA vaccine manufacturing plant , in the presence of EIB Vice-President Ambroise Fayolle, Aliou Ndiaye, Secretary General of the Senegalese Ministry of Economy, Planning and Cooperation, Dr Amadou Alpha Sall, Director of the Institut Pasteur in Dakar, and Irène Mingasson , Ambassador and Head of the EU Delegation to Senegal. EIB financing will play a key role in increasing vaccine production capacity to respond to epidemics and endemic diseases in the region.

The new establishment of the Pasteur Institute of Dakar is under construction in Diamniadio, a city and special economic zone strategically located between Dakar, the capital of Senegal, the international airport and the “Port of the Future” of Ndayane. The state-of-the-art site includes a manufacturing platform for the production of epidemic vaccines, a high-volume production site for yellow fever vaccines and a training site for the production of next-generation vaccines.

Once the new manufacturing plant is complete and running at full capacity, up to 300 million vaccine doses will be produced annually for the African continent.

This large-scale financing will help to significantly increase Africa’s production capacity for medicines and vaccines to fight COVID-19 and other endemic diseases, thereby reducing its dependence on imports, which currently cover 99% of its vaccine needs. Once the new manufacturing plant is complete and operating at full capacity, up to 300 million doses of vaccine will be produced annually for the African continent. Aware of the challenge represented by this manufacturing plant, the EIB and the European Union have already donated 5 million euros in 2021 alongside other partners for the technical feasibility studies and the preparation of the MADIBA project. (Manufacturing in Africa for Disease Immunization and Building Autonomy) of the Dakar Institute. to accelerate the construction of this new vaccine production site.

“Having different levels of protection in different parts of the world will not help end the COVID-19 pandemic or control other vaccine-preventable diseases. Building decentralized vaccine manufacturing capacity is critical to addressing this imbalance and ultimately building a safer and healthier world,” said Doctor Amadou Alpha Sall, director of the Institut Pasteur in Dakar. “We need to build a thriving ecosystem for vaccine production in Africa to achieve the level of resilience we all need. Expanding capacity in all vaccine-related sectors will create significant employment opportunities for thousands of young Africans.

“I am delighted that the EIB is one of the main financiers of the Pasteur Institute in Dakar. This new vaccine manufacturing plant is a vital project for public health in Senegal and across the African continent, contributing to greater autonomy in the production and distribution of essential vaccines,” said the EIB Vice President. . Ambroise Fayolle. “With EIB Global, our goal is to work as closely as possible with our partners to meet the needs of Senegalese, support growth and employment, and improve their daily lives in key areas such as health and access to care. This project is also a concrete example of the joint approach of the European Union in Africa through Team Europe.

“The MADIBA project demonstrates the commitment of the European Union and Team Europe to defend the fundamental principle of solidarity which binds us to all the countries of Africa. Since the beginning of the coronavirus pandemic, we have maintained that no one is safe until everyone is safe. We must therefore work together to ensure equal access to vaccines around the world,” said Irene Mingasson, Head of the EU Delegation to Senegal.

This financing is part of a major European investment program with Team Europe and its partners. The EIB, through its dedicated development arm (EIB Global), is a key player in supporting manufacturing and access to vaccines, medicines and health technologies in Africa.

The EIB has become one of Senegal’s most important development partners, investing a total of nearly €900 million since 1966 to improve living conditions in towns and rural communities, boost the economy and help businesses, small project developers and society adapt to climate change. .

Distributed by APO Group on behalf of the European Investment Bank (EIB).

About Joan Dow

Check Also

Salvadoran Leader Boosting Bitcoin May Have Doubts

SAN SALVADOR, El Salvador — The Salvadoran president of Bitcoin may have doubts about the …